8-K - MDNC - Equibles

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549____________________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934 Date

of Report (Date of earliest event reported): March 31, 2023

Medinotec Inc.

(Exact name of registrant as specified in its charter)

Nevada	333-265368	36-4990343
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
Northlands Deco Park	10 New Market Street	Stand<br> 299 Avant Garde Avenue<br><br> <br>North Riding	Johannesburg	South Africa	2169
---	---
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: +27 87 330

2301

________________________________________________<br><br> <br>(Former name or former address, if changed since last<br> report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ]	Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)
[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Item 7.01 Regulation FD Disclosure.

On March 30, 2023, Medinotec, Inc. (the “Company”) was notified by OTC Markets concerning the Company’s approval to be launched on OTCQX US on Friday, March 31, 2023. The Company issued a press release on the approval, which is furnished with this Current Report on Form 8-K as Exhibit 99.1.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under such section, nor shall it be deemed incorporated by reference in any of our filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.

Item 9.01	Financial Statements and Exhibits.
Exhibit No.	Description
---	---
99.1	Press Release, dated March 31, 2023

| 2 |

| --- |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Medinotec Inc.

/s/ Pieter van Niekerk

Pieter van Niekerk

Chief Financial Officer

Date: March 31, 2023

| 3 |

| --- |

OTCMarkets Group Welcomes Medinotec Inc. to OTCQX

Press Release | 03/31/2023

NEW YORK, March 31, 2023 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for 12,000 U.S. and international securities, today announced Medinotec Inc. (OTCQX: MDNC), a US-based company with a primary investment in DISA Medinotec, has qualified to trade on the OTCQX® Best Market.

Medinotec Inc. qualified for quotation on OTCQX under the symbol “MDNC.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

The OTCQX Market provides investors with a premium U.S. public market to research and trade the shares of investor-focused companies. Graduating to the OTCQX Market marks an important milestone for companies, enabling them to demonstrate their qualifications and build visibility among U.S. investors. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws.

“We are both proud and excited to have achieved this corporate milestone of being traded on the OTCQX Market. This represents the culmination of hard work and dedication of our management team to increase our exposure to financial markets and creating shareholder value while demonstrating our commitment to the highest corporate governance and reporting standards. I believe this will further support our endeavors in being a proud innovator and manufacturer of novel and quality minimally invasive surgical devices,” said Gregory Vizirgianakis, Chief Executive Officer of Medinotec Inc.

“Trading on OTCQX is the culmination of years of hard work, dedication and preparation which will allow Medinotec to execute its business plan to its fullest potential. Today marks the starting point of our journey as a publicly traded company and I am privileged and proud to form part of the team that will continue to grow the company and create shareholder value on a globally recognized platform, which is renowned for its high financial standards and stakeholder transparency,” said Pieter van Niekerk, Chief Financial Officer of Medinotec Inc.

B. Riley Securities, Inc. acted as the company’s OTCQX sponsor.

AboutMedinotec Inc.

Medinotec Inc. is a US-based company with a primary investment in DISA Medinotec (“Medinotec”), a South African medical device manufacturing and distribution company, which in managements opinion is a global leader in tracheal non-occlusive airway dilation technology and medical device design. The Group has experience in establishing facilities for the manufacturing and design of niche medical devices and establishing international distribution networks to commercialize these devices. Medinotec Inc. is seeking to expand sales and distribution operations into the US market and plans to enter the market with various products but initially focus on its Trachealtor product which won gold in the Medical Design Excellence Awards in 2021.

AboutOTC Markets Group Inc.

OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our three public markets: OTCQX® Best Market, OTCQB® Venture Market and Pink® Open Market.

Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets.

OTC Link ATS, OTC Link ECN and OTC Link NQB are each an SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

Subscribe to the OTC Markets RSS Feed

Media Contact:

OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com